GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Shandong Wohua Pharmaceutical Co 002107.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

6.00

+0.17%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Shandong Wohua Pharmaceutical Co

Its shares trade on Shenzhen under the ticker 002107.SZ. It has been listed since 24 January 2007. In the fiscal year to 31 December 2025, it reported revenue of CN¥817.0m and net income of CN¥95.7m. At that date it held total assets of CN¥977.4m and shareholders' equity of CN¥723.8m.

Shandong Wohua Pharmaceutical Co., Ltd. engages in the development, production and sales of natural plant-based cardiovascular and cerebrovascular proprietary Chinese medicines. The company is headquartered in Weifang, Shandong. The company went IPO on 2007-01-24. The firm's main products consist of Xinkeshu tablets for the treatment of coronary heart disease; Gushu tablets for the treatment of middle-aged and senile osteoporosis, and Hedan tablets for promoting blood circulation and for the treatment of hyperlipidemia. The firm distributes its products in domestic market, mainly in East China, North China and Northeast China.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
24 Jan 2007
Employees
1,415
Website
wohua.cn ↗

Leadership

Pay as last reported

  • Mr. Bingxian ZhaoChairman of the Board, since 2002
  • Ms. Yingzi ZengPresidentCN¥456,900
  • Ms. Caixia ZhaoVice Chairman of the Board, since 2024CN¥866,400
  • Mr. Jiong WangChief Financial Officer, Vice President, Secretary of the Board, Director, since 2010CN¥701,500
  • Ms. Qian YangVice President
  • Mr. Yong ChenDirector
  • Mr. Shengting LiDirectorCN¥240,000
  • Mr. Ge ZhangDirector, since 2003CN¥659,000
  • Ms. Mingqin GaoIndependent Director
  • Mr. Junde LiIndependent DirectorCN¥120,000
  • Mr. Junli YuIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Shandong Wohua Pharmaceutical employs 1,415 full-time employees in Weifang, CN.
  • Xinkeshu tablets treat coronary heart disease in East China markets.
  • Gushu tablets target middle-aged and senile osteoporosis in North China.

Weaknesses

  • Hedan tablets promote blood circulation for hyperlipidemia in Northeast China.
  • The company's domestic market focus limits international expansion opportunities.
  • Shandong Wohua's products are limited to cardiovascular and cerebrovascular treatments.

Opportunities

  • Expanding into East China's growing health care sector for cardiovascular products.
  • Increasing demand for natural plant-based medicines in North China.
  • Potential growth in Northeast China's market for Hedan tablets.

Threats

  • Competition from other pharmaceutical companies in East China.
  • Regulatory changes affecting natural plant-based medicine sales.
  • Economic downturns impacting health care spending in North China.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.